NCT06157918

Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants

A Single-Center, Randomized, Open-label, Single-dose, 3-Sequence, 3-Period Rossover Design to Evaluate the Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd · Industry
• Sex: Male
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This is a three-period crossover phase I study designed to evaluate the relative bioavailability, food effect, safety and tolerability of SYHA1813 oral solution in healthy participants.

Detailed description

Avoid duplicating information that will be entered elsewhere, such as Eligibility Criteria or Outcome Measures.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	SYHA1813 oral solution (2.0g:25mg)	SYHA1813 oral solution, 25mg, oral
DRUG	SYHA1813 oral solution (20ml:200mg)	SYHA1813 oral solution, 25mg, oral

Timeline

• Start date: 2023-12-20
• Primary completion: 2024-01-26
• Completion: 2024-01-26
• First posted: 2023-12-06
• Last updated: 2024-11-08

Locations

1 site across 1 country: China